Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

MYOS CORP Announces Launch of Equine Muscle Formula on Heels of Successful Clinical Trial on Palatability of Fortetropin® with Horses


News provided by

MYOS Corp.

Apr 26, 2023, 11:30 ET

Share this article

Share toX

Share this article

Share toX


MYOS Equine Muscle Formula® Represents Company's Entrance Into Lucrative Equine Market

CEDAR KNOLLS, N.J., April 26, 2023 /PRNewswire-PRWeb/ -- MYOS CORP, a research-based, advanced nutrition company, today announced the positive results of a study to determine the palability of its proprietary muscle health ingredient, Fortetropin®, with horses. With this positive study in hand, MYOS is planning an entrance into the lucrative equine industry with a May 2023 launch of a new product, MYOS Equine Muscle Formula®.

The equine palability study took place over two weeks at the Petaluma Equine Center in Petaluma, CA. The study consisted of 15 horses separated into three groups. Each group was fed daily either a placebo (cheese powder), 24g of Fortetropin, or 48g of Fortetropin. Serum chemistry, hematology, and fibrinogen, as well as physical exams and body weight were measured prior to the study; on the first day of administration and at the conclusion of the study. Physical exams were unchanged throughout the study. No clinically significant changes were observed in serum chemistry, hematology, and fibrinogen pre & post administration of Fortetropin.

“MYOS recognizes the importance of the equine market and the significant potential benefits of Fortetropin,” said MYOS CORP CEO Joe Mannello. "We believe a safe, all-natural muscle building product for horses has the potential to revolutionize the industry.”

Post this

"No adverse events were observed in any of the horses in all three groups receiving placebo or the sweetened formulation of Fortetropin," said the lead investigator Dr. Daizie Labelle, DVM, MBA, CCRP. "Horses readily ate this formulation top dressed on moistened stable mix pellets. Our data suggest that horses tolerate Fortetropin at doses of 72-109mg/kg."

Research on the muscle health efficacy of Fortetropin has been conducted with humans, canines, and felines. The product has been clinically shown to increase the rate of muscle protein synthesis, increase lean muscle mass, and reduce muscle atrophy.

For horses, muscle atrophy is a serious problem that can arise from conditions such as Cushing's disease, disuse atrophy, injury, malnutrition, and various genetic or immune-mediated myopathies. To be able to provide a safe, all-natural dietary supplement that can counteract the effects of atrophy can be a significant step forward in equine health.

Despite the lack of an equine-specific offering from MYOS until now, several prominent horse trainers have been giving their animals Fortetropin for years.

"There are other products in the equine market that address muscle, but none of them work as good as this!" said leading equine sports veterinarian Geoff Vernon, DVM.

According to a report by ResearchAndMarkets.com, the global equine industry was valued at $300 billion in 2020, and it is projected to reach $405 billion by 2026, growing at a compound annual growth rate (CAGR) of 5.2% during the forecast period. In the United States alone, the equine industry contributes approximately $122 billion to the economy annually. According to the American Horse Council Foundation's National Economic Impact Study, there are approximately 7.2 million horses in the United States. Other countries with large equine industries include China, Japan, Germany, France, and the United Kingdom.

"MYOS recognizes the importance of the equine market and the significant potential benefits of Fortetropin," said MYOS CORP CEO Joe Mannello. "With eight clinical studies supporting Fortetropin's ability to increase lean muscle mass and speed up recovery, this presents an excellent opportunity to expand our presence in this market. Prior to entering the equine market, we received positive feedback from Equine Vets who had success using Fortetropin. We believe a safe, all-natural muscle building product for horses has the potential to revolutionize the industry."

The equine industry encompasses a wide range of activities, including horse racing, breeding, training, showing, recreational riding, and therapeutic riding. It also includes a variety of supporting industries, such as feed and equipment manufacturers, veterinarians, and transportation providers.

About MYOS CORP.
MYOS CORP is a Cedar Knolls, NJ-based medical nutrition company that develops products that improve muscle health in people and animals. MYOS is the owner of Fortetropin®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin has been clinically shown to increase muscle size, lean body mass, and reduce muscle atrophy. MYOS products include MYOS Canine Muscle Formula® (Original & Vet Formula), MYOS Feline Muscle Formula®, and YOLKED®. For more information, please visit http://www.myospet.com. If you have any questions please contact mailto:[email protected] [[email protected] __title__ null].

Media Contact

Kris Ohrenick, MYOS Corp. , 1 973-509-0444 Ext: 2, [email protected]

SOURCE MYOS Corp.

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.